

## References

I-160

1. PROBUPHINE® (buprenorphine) implant subdermal administration [package insert]. Princeton, NJ. Braeburn Pharmaceuticals, Inc. 2016.
2. Micromedex® Healthcare Series. DrugDex Compendium®. PROBUPHINE® (buprenorphine). 2016.
3. Clinical pharmacology compendium. PROBUPHINE® (buprenorphine). 2016.
4. Rosenthal R, Lofwall M, Kim S, et al. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: A randomized clinical trial. *Journal of the American Medical Association*. 2016; 316(3):282-290.
5. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM). National practice guideline for the use of medications in the treatment of addiction involving opioid Use. *Journal of Addiction Medicine*. 2015; 9(5):358-367.
6. Woody G. Advances in the treatment of opioid use disorders. *F1000 Research*. 2017; 6:87